Citigroup’s Cardio Diagnostics CDIO Stock Holding History

Citigroup’s Portfolio CDIO Stock Details CDIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$359	Buy	+189	New	+$352	﹤0.01%	5602
2026 Q2	–	Sell	-1	Closed	-$2	–	5784
2026 Q1	$2	Sell	1 -25	-96%	-$65	﹤0.01%	5824
2025 Q4	$70	Buy	+26	New	+$95	﹤0.01%	5686
2025 Q1	–	Sell	-30	Closed	-$825	–	5624
2024 Q4	$825	Buy	+30	New	+$416	﹤0.01%	5608

Other funds holding CDIO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Citigroup's CDIO Position: Q3 2026 in Review

Citigroup opened a new position in Cardio Diagnostics (CDIO) in Q3 2026: 189 shares worth $359. The stake represents ﹤0.01% of the portfolio and ranks #5602 among its holdings. This is a return to the name: Citigroup previously reported a position in CDIO as recently as Q1 2026.

Citigroup first reported a position in CDIO in Q4 2024 and has held it in 4 quarters since. The position peaked at $825 in Q4 2024. 3 funds tracked by Wall St. Rank hold CDIO as of Q3 2026.

Citigroup held 189 shares of Cardio Diagnostics worth $359 as of Q3 2026.
Cardio Diagnostics was a new Citigroup position in Q3 2026.
Cardio Diagnostics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5602 holding.
Citigroup first reported a position in Cardio Diagnostics in Q4 2024 and has held it in 4 quarters since.
Citigroup's Cardio Diagnostics position peaked at $825 in Q4 2024.
3 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.